Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Madison, Wisconsin 53792


Purpose:

Patients will receive 6 to 8 cycles of R-CHOP (Rituximab, Cyclophosphamide, doxorubicin, vincristine, and prednisone), with GM-CSF.


Study summary:

The objective of this study is to estimate complete response rates for patients treated with this regimen, to assess overall response rates, event-free survival and overall survival; and to assess toxicities associated with R-CHOP + GM-CSF. Patients will receive 6 to 8 cycles of R-CHOP (Rituximab, Cyclophosphamide, doxorubicin, vincristine, and prednisone), with GM-CSF.


Criteria:

Inclusion Criteria: - Histologically confirmed, CD20+ B cell diffuse large cell lymphoma, with measurable or evaluable disease - Having no prior chemotherapy, immunotherapy or radiotherapy except for one cycle of CHOP or R-CHOP. Exclusion Criteria: - Pregnant - Hepatitis B Surface Antigen positive - Have known CNS disease or HIV infection - Have NY Classification III or IV disease.


NCT ID:

NCT00582725


Primary Contact:

Principal Investigator
Brad Kahl, MD
University of Wisconsin, Madison


Backup Contact:

N/A


Location Contact:

Madison, Wisconsin 53792
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.